ocrevus price
Garren confirmed that Ocrevus is priced at $65,000 per year. He again underscored that this is about 25 percent lower than Rebif (interferon beta 1-a) â a commonly used first-line option for relapsing MS, and the drug to which Ocrevus was compared in the OPERA trials.